Literature DB >> 8174677

Identification of a 130-kilodalton tyrosine-phosphorylated protein induced by interleukin-11 as JAK2 tyrosine kinase, which associates with gp130 signal transducer.

T Yin1, K Yasukawa, T Taga, T Kishimoto, Y C Yang.   

Abstract

Interleukin-11 (IL-11) shares the common signal transducer gp130 with IL-6, leukemia inhibitory factor (LIF), and oncostatin M (OSM) and triggers activation of unknown tyrosine kinases as the early steps of signal transduction pathway. Here we identify a 130-kilodalton tyrosine-phosphorylated protein induced by IL-11 in 3T3-L1 cells as JAK2 tyrosine kinase. We further show that the in vitro kinase activity of JAK2 is greatly enhanced following stimulation with IL-11 in 3T3-L1 cells and TF-1 cells. Furthermore, we demonstrate that JAK2 physically associates with the signal transducer gp130. Similar results were observed following stimulation with IL-6, LIF, and OSM. However, we were unable to show that JAK1 is tyrosine phosphorylated and activated by IL-11 under identical conditions. These results suggest that JAK2 tyrosine kinase is one of the tyrosine kinases involved in signal transduction mediated by IL-11, IL-6, LIF, and OSM.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8174677

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  11 in total

Review 1.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

2.  Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family.

Authors:  G Senaldi; B C Varnum; U Sarmiento; C Starnes; J Lile; S Scully; J Guo; G Elliott; J McNinch; C L Shaklee; D Freeman; F Manu; W S Simonet; T Boone; M S Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

3.  Negative cross-talk between interleukin-3 and interleukin-11 is mediated by suppressor of cytokine signalling-3 (SOCS-3).

Authors:  F Magrangeas; O Boisteau; S Denis; Y Jacques; S Minvielle
Journal:  Biochem J       Date:  2001-01-15       Impact factor: 3.857

4.  Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma.

Authors:  C L Campbell; Z Jiang; D M Savarese; T M Savarese
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

5.  Expression and function of interleukin-11 and its receptor alpha in the human endometrium.

Authors:  Natalia Karpovich; Katya Chobotova; Janet Carver; John K Heath; David H Barlow; Helen J Mardon
Journal:  Mol Hum Reprod       Date:  2003-02       Impact factor: 4.025

6.  The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures.

Authors:  E Romas; N Udagawa; H Zhou; T Tamura; M Saito; T Taga; D J Hilton; T Suda; K W Ng; T J Martin
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

7.  IL-11 Attenuates Liver Ischemia/Reperfusion Injury (IRI) through STAT3 Signaling Pathway in Mice.

Authors:  Miao Zhu; Bo Lu; Qinhong Cao; Zhenfeng Wu; Zhe Xu; Weisu Li; Xuequan Yao; Fukun Liu
Journal:  PLoS One       Date:  2015-05-06       Impact factor: 3.240

8.  An amino acid substitution in the Drosophila hopTum-l Jak kinase causes leukemia-like hematopoietic defects.

Authors:  H Luo; W P Hanratty; C R Dearolf
Journal:  EMBO J       Date:  1995-04-03       Impact factor: 11.598

9.  Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells.

Authors:  D Chauhan; S M Kharbanda; A Ogata; M Urashima; D Frank; N Malik; D W Kufe; K C Anderson
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

10.  Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors.

Authors:  N Udagawa; N Takahashi; T Katagiri; T Tamura; S Wada; D M Findlay; T J Martin; H Hirota; T Taga; T Kishimoto; T Suda
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.